Codexis, Inc. (CDXS) |
11.44 1.01 (9.68%)
|
06-26 22:01 |
Open: |
10.43 |
Pre. Close: |
10.43 |
High:
|
11.44 |
Low:
|
10.52 |
Volume:
|
1,598,046 |
Market Cap:
|
747(M) |
|
|
Codexis, Inc. discovers, develops, and sells enzymes and other proteins. It offers biocatalyst products and services; intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. It sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California. |
Stock Price Prediction |
Update at 5:00pm EST |
If tomorrow:
|
Open lower
|
Open higher
|
High:
|
11.44 - 11.48 |
11.48 - 11.52 |
Low:
|
10.41 - 10.46 |
10.46 - 10.5 |
Close:
|
11.36 - 11.43 |
11.43 - 11.5 |
|
Technical analysis |
as of: 2022-06-24 4:38:44 PM |
Overall:
|
|
Stoxline posted a BUY today, same as yesterday. Upward movement continues. |
Target: |
Six months: 13.36 One year: 15.6  |
Support: |
Support1: 9.38 Support2: 8.1 |
Resistance: |
Resistance1: 11.43 Resistance2: 13.36  |
Pivot: |
9.49  |
Moving Average: |
MA(5): 9.99 MA(20): 9.74 
MA(100): 15.32 MA(250): 22.68  |
MACD: |
MACD(12,26): -0.4 Signal(9): -0.7  |
Stochastic oscillator: |
%K(14,3): 84.9 %D(3): 65.6  |
RSI: |
RSI(14): 59.8  |
52-week: |
High: 42 Low: 8.1 |
Average Vol(K): |
3-Month: 875 (K) 10-Days: 901 (K) |
|
Price, moving averages and Bollinger Bands |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ CDXS ] has closed above the upper band by 12.2%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 28.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
Headline News |
Sun, 26 Jun 2022 Codexis to Participate in Upcoming Healthcare Conferences - GuruFocus.com
Fri, 24 Jun 2022 Is Codexis, Inc. (CDXS) a Good Choice in Biotechnology Friday? - InvestorsObserver
Fri, 17 Jun 2022 Codexis rises 8% on publication of research for protein modification (NASDAQ:CDXS) - Seeking Alpha
Wed, 15 Jun 2022 Codexis (NASDAQ:CDXS) Sets New 12-Month Low at $8.68 - Defense World
Mon, 06 Jun 2022 Even though Codexis (NASDAQ:CDXS) has lost US$59m market cap in last 7 days, shareholders are still up 118% over 5 years - Simply Wall St
Sat, 04 Jun 2022 Companies Like Codexis (NASDAQ:CDXS) Are In A Position To Invest In Growth - Yahoo Movies UK
|
Financial Analysis |
Price to Book Value: |
Outperform |
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Price to Earnings: |
Underperform |
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Discounted cash flow: |
Outperform |
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Return on Assets: |
Neutral |
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Return on Equity: |
Neutral |
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Debt to Equity: |
Neutral |
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
Free Technical Analysis Charts
|
|
Stock Basics & Statistics |
Exchange: NASDAQ |
Sector: Healthcare |
Industry: Biotechnology |
Shares Out. |
65 (M) |
Shares Float |
56 (M) |
% Held by Insiders
|
2.4 (%) |
% Held by Institutions
|
106.4 (%) |
Shares Short
|
4,990 (K) |
Shares Short P.Month
|
4,810 (K) |
Stock Financials |
EPS
|
-0.24 |
EPS Est Next Qtl
|
0.05 |
EPS Est This Year
|
-0.42 |
EPS Est Next Year
|
-0.16 |
Book Value (p.s.)
|
2.6 |
Profit Margin (%)
|
-20.4 |
Operating Margin (%)
|
-21.7 |
Return on Assets (ttm)
|
-6.1 |
Return on Equity (ttm)
|
-12.8 |
Qtrly Rev. Growth
|
16.5 |
Gross Profit (p.s.)
|
0.41 |
Sales Per Share
|
1.61 |
EBITDA (p.s.)
|
-0.31 |
Qtrly Earnings Growth
|
0 |
Operating Cash Flow
|
-14 (M) |
Levered Free Cash Flow
|
-14 (M) |
Stock Valuations |
PE Ratio
|
-47.67 |
PEG Ratio
|
-1.5 |
Price to Book value
|
4.38 |
Price to Sales
|
7.08 |
Price to Cash Flow
|
-52.02 |
Stock Dividends |
Dividend
|
0 |
Forward Dividend
|
0 |
Dividend Yield
|
0% |
Dividend Pay Date
|
Invalid DateTime. |
Ex-Dividend Date
|
Invalid DateTime. |
7 Binary Options
|
Your Ad Here
|
|